Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice

Toxicology and Applied Pharmacology

Volumn 160, Issue 2, 1999, Pages 120-126

  Constan, Alexander A ^a   Sprankle, Catherine S ^a   Peters, Jeffrey M ^b   Kedderis, Gregory L ^a   Everitt, Jeffrey I ^a   Wong, Brian A ^a   Gonzalez, Frank L ^b   Butterworth, Byron E ^a  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; CHLOROFORM; DIMETHYLNITROSAMINE DEMETHYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; HISTOPATHOLOGY; LIVER TOXICITY; MALE; METABOLIC INHIBITION; MOUSE; NEPHROTOXICITY; NONHUMAN; NOSE IRRITATION; SYMPTOM; TISSUE REGENERATION; TOXICOKINETICS;

ANIMALIA; RODENTIA;

EID: 0032732171     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8756     Document Type: Article

References (41)

1. Butler E. C. V., Dal Pont G. Liquid chromatography electrochemistry procedure for determination of chlorophenolic compounds in pulp mill effluents and receiving waters. J. Chromatogr. 609:1992;113-123.
2. Butterworth B. E., Bogdanffy M. S. A comprehensive approach for integration of toxicity and cancer risk assessments. Regul. Toxicol. Pharmacol. 29:1999;23-36.
3. Butterworth B. E., Conolly R. B., Morgan K. T. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. Cancer Lett. 93:1995;129-146.
4. Conolly R. B., Andersen M. E. Biologically based pharmacodynamic models: Tools for toxicological research and risk assessment. Annu. Rev. Pharmacol. Toxicol. 31:1991;503-523.
5. Conolly R. B., Butterworth B. E. Biologically based dose response model for hepatic toxicity: A mechanistically based replacement for traditional estimates of noncancer risk. Toxicol. Lett. 1995;901-906.
6. Corley R. A., Mendrala A. L., Smith F. A., Staats D. A., Gargas M. L., Conolly R. B., Andersen M. E., Reitz R. H. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol. Appl. Pharmacol. 103:1990;512-527.
7. 14C]chloroform hepatotoxicity: Covalent interaction of a reactive intermediate with rat liver phospholipid. Toxicol. Appl. Pharmacol. 73:1984;478-491.
8. Craun G. F. Safety of Water Disinfection: Balancing Chemical and Microbial Risks. 1993;ILSI Press, Washington.
9. Davison M. H. A. Chloroform. Br. J. Anaesth. 37:1965;655-660.
10. Dorman D. C., Wong B. A., Struve M. F., James R. A., LaPerle M. D., Marshall M. W., Bolon B. Development of a mouse whole-body exposure system from a directed-flow, rat nose-only system. Inhal. Toxicol. 8:1996;107-120.
11. 3H]thymidine administered by injection or osmotic pump. Carcinogenesis. 11:1990;2245-2251.
12. Ilett K. F., Reid W. D., Sipes I. G., Krishna G. Chloroform toxicity in mice: Correlation of renal and hepatic necrosis with covalent binding of metabolites to tissue macromolecules. Exp. Mol. Pathol. 19:1973;215-229.
13. International Life Sciences Institute (ILSI), 1997, An Evaluation of EPA's Proposed Guidelines for Carcinogen Risk Assessment Using Chloroform and Dichloroacetate As Case Studies: Report of an Expert Panel, International Life Sciences Institute, 1126 Sixteenth St, N.W. Washington, DC.
14. International Programme on Chemical Safety (IPCS), 1994, Environmental Health Criteria 163: Chloroform, 174 pp, World Health Organization, Geneva, Switzerland.
15. Jo W. K., Weisel C. P., Lioy P. J. Routes of chloroform exposure and body burden from showering with chlorinated tap water. Risk Anal. 10:1990;575-580.
16. 1 mice. Fundam. Appl. Toxicol. 5:1985;760-769.
17. 1 mice. Environ. Mol. Mutagen. 23:1994a;132-136.
18. 1 mice: Comparison of administration by gavage in corn oil vs. ad libitum in drinking water. Fundam. Appl. Toxicol. 22:1994b;90-102.
19. 1 mice given chloroform by gavage. Fundam. Appl. Toxicol. 23:1994c;537-543.
20. 1 mice and male F-344 rats. Fundam. Appl. Toxicol. 22:1994d;431-446.
21. 1 mice: Implications for cancer risk assessment. Fundam. Appl. Toxicol. 30:1996;118-137.
22. Lee S. T., Buters J. T. M., Pineau T., Fernandez-Salguero P., Gonzalez F. J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271:1996;12063-12067.
23. Mansuy D., Beaune P., Cresteil T., Lange M., Leroux J. P. Evidence for phosgene during liver microsomal oxidation of chloroform. Biochem. Biophys. Res. Commun. 79:1977;513-517.
24. 1 mice following a 1-week inhalation exposure. Toxicol. Appl. Pharmacol. 125:1994;214-227.
25. Meschter C. L., Mico B. A., Mortillo M., Feldman D., Garland W. A., Riley J. A., Kaufman L. S. A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats. Fundam. Appl. Toxicol. 22:1994;369-381.
26. Mico B. A., Federowicz D. A., Ripple M. G., Kerns W. In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT): A tool for biochemical toxicology. Biochem. Pharmacol. 37:1988;2515-2519.
27. Morgan K. T. Approaches to the identification and recording of nasal lesions in toxicology studies. Toxicol. Pathol. 19:1991;337-531.
28. Nakajima T., Eloovara E., Okino T., Gelboin H. V., Klockars M., Riihimaki V., Aoyama T., Vainio H. Different contributions of cytochrome P450 2E1 and P450 2B1/2 to chloroform hepatotoxicity in rat. Biochem. Pharmacol. 133:1995;215-222.
29. National Cancer Institute (NCI), 1976, Carcinogenesis Bioassay of Chloroform, National Technical Information Service No. PB264018/AS, Bethesda, MD.
30. Guide for the Care and Use of Laboratory Animals. 1996;National Academic Press, Washington.
31. Pohl L. R., Bhooshan B., Whittaker N. F., Krishna G. Phosgene: A metabolite of chloroform. Biochem. Biophys. Res. Commun. 79:1977;684-691.
32. Reitz R. H., Mendrala A. L., Corley R. A., Quast J. F., Gargas M. L., Andersen M. E., Staats D. A., Conolly R. B. Estimating the risk of liver cancer associated with human exposures to chloroform. Toxicol. Appl. Pharmacol. 105:1990;443-459.
33. Singh H. B., Salas L. J., Stiles R. E. Distribution of selected gaseous organic mutagens and suspect carcinogens in ambient air. Environ. Sci. Technol. 16:1982;872-880.
34. Smith J. H., Hook J. B. Mechanism of chloroform nephrotoxicity. III. Renal and hepatic microsomal metabolism of chloroform in mice. Toxicol. Appl. Pharmacol. 73:1984;511-524.
35. Smith J. H., Maita K., Sleight S. D., Hook J. B. Mechanism of chloroform nephrotoxicity. I. Time course of chloroform toxicity in male and female mice. Toxicol. Appl. Pharmacol. 70:1983;467-479.
36. Symons J. M., Bellar T. A., Carswell J. K., DeMarco J., Kropp K. L., Robeck G. G., Seeger D. R., Slocum C. J., Smith B. L., Stevens A. A. National organics reconnaissance survey for halogenated organics. J. Am. Water Works Assoc. 67:1975;634.
37. Uden P. C., Miller J. W. Chlorinated acids and chloral in drinking water. J. Am. Water Works Assoc. 75:1983;524-526.
38. U.S. Environmental Protection Agency 1998. National Primary Drinking Water Regulations; Disinfectants and Disinfection Byproducts Notice of Data Availability; Proposed Rule. Fed. Reg.63, March 31, 1998, 15673-15692.
39. Valentine J. L., Lee S. T., Seaton M. J., Asgharian B., Farris G., Corton J. C., Gonzalez F. J., Medinsky M. A. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol. Appl. Pharmacol. 141:1996;205-213.
40. Whitaker A. M., Jones C. S. Report of 1500 chloroform anesthetics administered with a precision vaporizer. Anesthes. Analgesia. 44:1965;60-65.
41. 1 mice. Proceedings of the Fifty-third Annual Meeting of the Japanese Cancer Association. 1994.